At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GNTA Genenta Science S.p.A.
Not Yet Opened 03-31 16:00:00 EDT
3.97
+0.00
0.00%
盘后3.85
-0.12-3.02%
16:01 EDT
High4.15
Low3.97
Vol7.98K
Open4.07
D1 Closing3.97
Amplitude4.53%
Mkt Cap72.61M
Tradable Cap44.57M
Total Shares18.29M
T/O31.75K
T/O Rate0.07%
Tradable Shares11.23M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Genenta Science Obtains $21.9 Million Financing to Expand Pipeline
Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.